<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24612502</article-id><article-id pub-id-type="pmc">3984742</article-id><article-id pub-id-type="publisher-id">1471-2407-14-170</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-170</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Kim</surname><given-names>Jisun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>leticeclear@naver.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Lim</surname><given-names>Woosung</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>limw@ewha.ac.kr</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Kim</surname><given-names>Eun-Kyu</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>kimek@kcch.re.kr</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Kim</surname><given-names>Min-Kyoon</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>likeicetea@hanmail.net</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Paik</surname><given-names>Nam-Sun</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>namsun.paik@gmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Jeong</surname><given-names>Sang-Seol</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>ssjung@catholic.ac.kr</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Yoon</surname><given-names>Jung-han</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jhyoon@chonnam.ac.kr</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Park</surname><given-names>Chan Heun</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>chanheun.park@samsung.com</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Ahn</surname><given-names>Sei Hyun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ahnsh@amc.seoul.kr</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Kim</surname><given-names>Lee Su</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>lskim0503@hallym.ac.kr</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Han</surname><given-names>Sehwan</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>breast@hanmail.net</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Nam</surname><given-names>Seok Jin</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>seokjin.nam@samsung.com</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Kang</surname><given-names>Han-Sung</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>rorerr@ncc.re.kr</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Kim</surname><given-names>Seung Il</given-names></name><xref ref-type="aff" rid="I12">12</xref><email>skim@yuhs.ac</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Yoo</surname><given-names>Young Bum</given-names></name><xref ref-type="aff" rid="I13">13</xref><email>0117652771@kuh.ac.kr</email></contrib><contrib contrib-type="author" id="A16"><name><surname>Jeong</surname><given-names>Joon</given-names></name><xref ref-type="aff" rid="I14">14</xref><email>GSJJOON@yuhs.ac</email></contrib><contrib contrib-type="author" id="A17"><name><surname>Kim</surname><given-names>Tae Hyun</given-names></name><xref ref-type="aff" rid="I15">15</xref><email>kitah@hanmail.net</email></contrib><contrib contrib-type="author" id="A18"><name><surname>Kang</surname><given-names>Taewoo</given-names></name><xref ref-type="aff" rid="I16">16</xref><email>taewoo.d.kang@gmail.com</email></contrib><contrib contrib-type="author" id="A19"><name><surname>Kim</surname><given-names>Sung-Won</given-names></name><xref ref-type="aff" rid="I17">17</xref><email>brca@korea.com</email></contrib><contrib contrib-type="author" id="A20"><name><surname>Jung</surname><given-names>Yongsik</given-names></name><xref ref-type="aff" rid="I18">18</xref><email>drjys@ajou.ac.kr</email></contrib><contrib contrib-type="author" id="A21"><name><surname>Lee</surname><given-names>Jeong Eon</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>paojlus@hanmail.net</email></contrib><contrib contrib-type="author" id="A22"><name><surname>Kim</surname><given-names>Ku Sang</given-names></name><xref ref-type="aff" rid="I18">18</xref><email>ideakims@gmail.com</email></contrib><contrib contrib-type="author" id="A23"><name><surname>Yu</surname><given-names>Jong-Han</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lymbics@hanmail.net</email></contrib><contrib contrib-type="author" id="A24"><name><surname>Chae</surname><given-names>Byung Joo</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>bjcgs@naver.com</email></contrib><contrib contrib-type="author" id="A25"><name><surname>Jung</surname><given-names>So-Youn</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>goje1@ncc.re.kr</email></contrib><contrib contrib-type="author" id="A26"><name><surname>Kang</surname><given-names>Eunyoung</given-names></name><xref ref-type="aff" rid="I17">17</xref><email>key5002@gmail.com</email></contrib><contrib contrib-type="author" id="A27"><name><surname>Choi</surname><given-names>Su Yun</given-names></name><xref ref-type="aff" rid="I19">19</xref><email>choisuyun@hallym.or.kr</email></contrib><contrib contrib-type="author" id="A28"><name><surname>Moon</surname><given-names>Hyeong-Gon</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I20">20</xref><email>moonhg74@snu.ac.kr</email></contrib><contrib contrib-type="author" id="A29"><name><surname>Noh</surname><given-names>Dong-Young</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I20">20</xref><email>dynoh@snu.ac.kr</email></contrib><contrib contrib-type="author" corresp="yes" id="A30"><name><surname>Han</surname><given-names>Wonshik</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I20">20</xref><email>hanw@snu.ac.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea</aff><aff id="I2"><label>2</label>Department of Surgery, Ewha Womans University School of Medicine, Seoul, Korea</aff><aff id="I3"><label>3</label>Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological &#x00026; Medical Sciences, Seoul, Korea</aff><aff id="I4"><label>4</label>Department of Surgery, Seoul National University Hospital, 101 Daehakro, Jongno-gu, Seoul 110-744, Korea</aff><aff id="I5"><label>5</label>Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea</aff><aff id="I6"><label>6</label>Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea</aff><aff id="I7"><label>7</label>Department of Surgery, Breast and Thyroid Cancer Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea</aff><aff id="I8"><label>8</label>Division of Breast and Endocrine Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea</aff><aff id="I9"><label>9</label>Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, Korea</aff><aff id="I10"><label>10</label>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</aff><aff id="I11"><label>11</label>Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea</aff><aff id="I12"><label>12</label>Department of Surgery, Yonsei University College of Medicine, Seoul, Korea</aff><aff id="I13"><label>13</label>Department of Surgery, College of Medicine, Konkuk University, Seoul, Korea</aff><aff id="I14"><label>14</label>Breast Cancer Center, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</aff><aff id="I15"><label>15</label>Department of Surgery, Inje University, Busan Paik Hospital, Busan, Korea</aff><aff id="I16"><label>16</label>Busan Cancer Center, Department of Surgery, College of Medicine, Pusan National University, Busan, Korea</aff><aff id="I17"><label>17</label>Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea</aff><aff id="I18"><label>18</label>Department of Surgery, Ajou University School of Medicine, Suwon, Korea</aff><aff id="I19"><label>19</label>Division of Breast and Endocrine Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea</aff><aff id="I20"><label>20</label>Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2014</year></pub-date><volume>14</volume><fpage>170</fpage><lpage>170</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2012</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Kim et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kim et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/14/170"/><abstract><sec><title>Background</title><p>Neoadjuvant endocrine therapy with an aromatase inhibitor has shown efficacy comparable to that of neoadjuvant chemotherapy in patients with postmenopausal breast cancer. Preclinical and clinical studies have shown that the antidiabetic drug metformin has anti-tumor activity. This prospective, multicenter, phase II randomized, placebo controlled trial was designed to evaluate the direct anti-tumor effect of metformin in non-diabetic postmenopausal women with estrogen-receptor (ER) positive breast cancer.</p></sec><sec><title>Methods/Design</title><p>Patients meeting the inclusion criteria and providing written informed consent will be randomized to 24&#x000a0;weeks of neoadjuvant treatment with letrozole (2.5&#x000a0;mg/day) and either metformin (2000&#x000a0;mg/day) or placebo. Target accrual number is 104 patients per arm. The primary endpoint will be clinical response rate, as measured by calipers. Secondary endpoints include pathologic complete response rate, breast conserving rate, change in Ki67 expression, breast density change, and toxicity profile. Molecular assays will be performed using samples obtained before treatment, at week 4, and postoperatively.</p></sec><sec><title>Discussion</title><p>This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic, postmenopausal patients with ER-positive breast cancer.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov Identifier <ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov/ct2/show/NCT01589367?term=%22metformin%22+AND+%22breast+cancer%22&#x00026;rank=9">NCT01589367</ext-link></p></sec></abstract><kwd-group><kwd>Metformin</kwd><kwd>Letrozole</kwd><kwd>Neoadjuvant</kwd><kwd>Estrogen receptor-positive Breast cancer</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Metformin, which is commonly used to treat type 2 diabetes, is a relatively safe drug with known pharmacokinetics and manageable toxicities. In addition, numerous experimental, epidemiologic, observational, and clinical studies have shown that metformin has anti-tumor effects [<xref ref-type="bibr" rid="B1">1</xref>]. For example, in a preclinical mouse xenograft model, metformin reduced the effective dosages of standard chemotherapeutic drugs and had preferential effects on tumorigenic cells [<xref ref-type="bibr" rid="B2">2</xref>]. A retrospective clinical study showed that patients taking metformin during neoadjuvant chemotherapy had a higher pathologic complete response (pCR) rate than diabetic patients not taking metformin or non-diabetes patients (24% vs 8% vs 16%, p&#x02009;=&#x02009;0.02) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Two potential mechanisms of anti-cancer action of metformin have been suggested. First, metformin may directly activate adenosine monophosphate kinase (AMPK), resulting in the downstream inhibition of mTOR signaling and the consequent suppression of cell proliferation [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Second, metformin-induced decreases in circulating insulin and insulin-like growth factor (IGF) concentrations may reduce the activation of the IGF-receptor signaling axis, resulting in decreases in growth promotion and mitogenesis [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Thus, the anti-cancer effects of metformin are mediated through a systemic improvement in metabolic profile and by directly targeting tumor cells [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Questions remain, however, about the clinical benefits of metformin as an anti-cancer agent in patients with breast cancer. Although one large-scale, phase III trial of adjuvant metformin has been initiated in women with breast cancer (NCIC CTG MA.32) [<xref ref-type="bibr" rid="B1">1</xref>], the accrual and treatment process is still ongoing, and several years of follow-up are needed to determine survival benefits. In addition, little is known about the effects of metformin on different subtypes of breast cancer or on the synergy between metformin and concurrently administered systemic agents. In addition, the optimal dosage of metformin that shows maximal anti-tumor effects with acceptable toxicities has not been determined. In this context, neoadjuvant treatment is the most efficient setting to assess the short-term in vivo effects of drug therapy in breast cancer patients. Neoadjuvant endocrine therapy results in a comparable response but lower toxicity compared with neoadjuvant chemotherapy in women with ER-positive breast cancer [<xref ref-type="bibr" rid="B13">13</xref>]. In postmenopausal women, aromatase inhibitors are associated with higher response rates than tamoxifen [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. A recent phase II trial found that neoadjuvant treatment with everolimus, an mTOR inhibitor, plus letrozole resulted in a better response rate than letrozole alone [<xref ref-type="bibr" rid="B16">16</xref>]. In addition, neoadjuvant metformin was shown to lower Ki67 level [<xref ref-type="bibr" rid="B17">17</xref>]. These results suggested that metformin may be effective, when combined with letrozole, in postmenopausal women with ER-positive breast cancer. We therefore designed and initiated a phase II clinical trial evaluating the anti-tumor effect of neoadjuvant metformin in postmenopausal women with ER-positive breast cancer by comparing treatment with letrozole plus metformin or placebo.</p></sec><sec><title>Methods/Design</title><sec><title>Study goal</title><p>The goal of this study was to evaluate the benefits of combining metformin and letrozole in the neoadjuvant treatment of postmenopausal women with ER-positive breast cancer. The primary end point is the rate of tumor response (clinical response rate) at 24&#x000a0;weeks, determined by measurements with calipers; changes in size on ultrasound, mammography, and MRI will be used as secondary efficacy assessments. Clinical response includes complete response (CR) and partial response (PR) by RECIST v1.1 criteria.</p></sec><sec><title>Study design</title><p>METEOR is a phase II, prospective, randomized, double-blinded, placebo-controlled multicenter clinical trial. Twenty-one centers belonging to the Korean Breast Cancer Society Study Group are participating in this study (KBCSG-013). Patients will be randomly assigned (1:1) to receive letrozole 2.5&#x000a0;mg/day plus either metformin or placebo for 24&#x000a0;weeks before surgery. The initial dose of metformin will be 1000&#x000a0;mg/day for the first week, followed by 1500&#x000a0;mg/day for the second week, and 2000&#x000a0;mg/day from the third week onward. Patients will be randomized sequentially, stratified by center, with randomization codes. Block randomization will be used (SAS 9.2) in cooperation with the Medical Research Collaborating Center (MRCC) of Seoul National University Hospital. All study personnel will be masked to treatment. This study protocol has been approved by the Korea Food and Drug Administration (KFDA) as well as the institutional review board of each center, and was registered at clinicaltrials.gov (NCT 01589367). Written informed consent was obtained from all participants.</p></sec><sec><title>Eligibility criteria and sample size calculation</title><p>Eligible patients are postmenopausal women with histologically confirmed ER-positive, stage II or III, primary breast cancer with palpable and clinically measureable tumors. The target population is 208 women, 104 in each arm. Sample size was calculated based on expected clinical response rates (cRR) of 55% in the letrozole plus placebo arm and 70% in the letrozole plus metformin arm, with &#x003b1;&#x02009;=&#x02009;0.10 and 80% power and including an estimated 10% drop out rate. ER positivity is defined as &#x02265;10% nuclear staining by immunohistochemistry or Allred score &#x02265;3. Criteria for determining menopause include bilateral oophorectomy, age &#x02265;60&#x000a0;years, or age &#x0003c;60&#x000a0;years and amenorrhea for &#x02265;12&#x000a0;months and FSH &#x0003e;30 mIU/ml. Patients with diabetes (HbA1c &#x02265;6.5% or fasting plasma glucose (FPG) &#x02265;126&#x000a0;mg/dL (&#x02265;7&#x000a0;mM)); clinical T4, N3, or M1 disease; bilateral cancer, or inflammatory breast cancer will be excluded, as will patients with a history of lactic acidosis or at high risk of having metformin-induced lactic acidosis, such as those with high alcohol consumption or NYHA class III/lV congestive heart failure.</p></sec><sec><title>Treatment schedule and evaluation</title><p>Patients will be randomly assigned (1:1) to 24&#x000a0;weeks of neoadjuvant treatment with metformin plus letrozole or placebo plus letrozole (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Medications will be distributed at each monthly visit, with compliance assessed by counting the remaining tablets.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Scheme of the METEOR trial.</bold> Patients meeting the inclusion criteria will be 1:1 randomized to 24&#x000a0;weeks of letrozole plus metformin or letrozole plus placebo. Core needle biopsies will be recommended after 4&#x000a0;weeks of treatment. Surgery will be performed within 2&#x000a0;weeks after the end of the 24&#x000a0;week treatment period.</p></caption><graphic xlink:href="1471-2407-14-170-1"/></fig><p>Tumor size will be measured clinically with calipers before treatment and sequentially every month. Each patient will undergo a careful physical examination at each monthly visit, and patients with progressive disease (PD) will be discontinued from the study and scheduled for immediate surgery. Patients with stable disease (SD) will be continued on treatment. Ultrasound-guided core needle biopsy samples will be obtained at the first visit and after four weeks of medication, with Ki67 levels in these samples centrally assessed. It is also recommended that 4-week blood samples be obtained to measure serum biomarker concentrations. Surgery will be scheduled within 2&#x000a0;weeks after completing the 24&#x000a0;weeks of medication. Tissue from surgical specimens will be collected for further planned assessments of biomarkers by paired analysis with the pretreatment and week 4 core needle biopsy specimens. HbA1c, FPG, insulin, c-peptide, and IGF-1 concentrations will be measured at baseline and after 12 and 24&#x000a0;weeks of treatment. Mammography, ultrasonography, and bilateral breast MRI will be performed before starting medication and after completion of treatment just before surgery.</p></sec><sec><title>Analysis of the results</title><p>The primary endpoint is cRR. Tumor response will be assessed by RECIST criteria v1.1. Tumor size will be measured by individual clinicians at monthly visits. The secondary endpoint is pathologic complete response (pCR), defined as the absence of invasive cancer at the primary site and in the axilla. Before treatment, each patients will be categorized by surgeons into one of three groups: 1) marginal for breast conservation, 2) candidate for mastectomy only, and 3) inoperable by standard mastectomy [<xref ref-type="bibr" rid="B18">18</xref>]. Baseline assessment and actually performed surgery will be compared. The breast conservation rate in each arm will be evaluated, and the toxicity profile of each arm will be assessed every 4&#x000a0;weeks using NCI-CTCAE version 4.0 (<ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/reporting/ctc.html">http://ctep.cancer.gov/reporting/ctc.html</ext-link>). All parameters will be collected and managed using an e-clinical trial platform (MEBICA&#x02122;).</p></sec><sec><title>Translational research project</title><p>In addition to assaying Ki-67, phosphorylated S6 kinase 1 (p-S6K1) will be analyzed by immunohistochemistry (IHC) in a central laboratory. Fresh frozen tissue of week 4 biopsies and final surgical specimens will be collected from several major hospitals participating in this study. These samples will be used for DNA microarray analysis or whole transcriptome sequencing using next generation sequencing (NGS) technology. Phosphorylation of AMPK(T172), expression of IR(insulin receptor) and OCT1(Organic cation transporter) will be measured. Assessment of apoptosis will be done by Miller-Payne Grading system along with various commercialized kits.</p><p>We previously reported that breast density reduction after short term adjuvant endocrine therapy was predictive of recurrence-free survival [<xref ref-type="bibr" rid="B19">19</xref>]. We intend to analyze the association between breast density reduction and response to endocrine therapy in this prospective trial. Pre- and post-medication mammography results and breast MRI images of all patients will be centrally reviewed. Breast density will be measured centrally using computer-assisted software, Cumulus (University of Toronto, Toronto Ontario, Canada), by a single observer. The density of both breasts will be assessed by breast MRI [<xref ref-type="bibr" rid="B20">20</xref>], with the cranio-caudal view of the contralateral breast used as a reference to evaluate the percent change in mammographic density.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The maximum effective dose of metformin to treat hyperglycemia in patients with type 2 diabetes is 1000&#x000a0;mg twice daily. However, the metformin dose that yields the maximal anti-tumor effect is unclear. Results from two xenograft models reported that the human equivalent of 1500&#x02013;2250&#x000a0;mg/day was needed to inhibit tumorigenesis [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. A preoperative window of opportunity trial in breast cancer patients utilized a dose of 2000&#x000a0;mg/day [<xref ref-type="bibr" rid="B24">24</xref>], whereas the ongoing NCIC CTG MA32 phase III clinical trial is testing the effect of adjuvant metformin, is utilizing a dosage of 1700&#x000a0;mg/day. To use the maximum dose of metformin in this neoadjuvant setting, as well as to ensure patient safety, the dose is gradually increased over the first few weeks of treatment, and doses may be adjusted in response to toxicities/adverse events. The results of this trial will provide important information on the optimally effective and safest dose of metformin in non-diabetic breast cancer patients.</p><p>This study was designed to evaluate the direct anti-tumor effects of metformin in human breast cancer cancers. We expect that metformin will show a synergy with neoadjuvant letrozole in ER-positive breast cancer patients similar to that of the mTOR inhibitor, everolimus. Parallel translational research may provide a better understanding of the mechanism of action of metformin in cancer and may reveal biomarkers predictive of response to metformin.</p></sec><sec><title>Abbreviations</title><p>ER: Estrogen receptor; AMPK: Adenosine monophosphate kinase; pCR: Pathologic complete response; mTOR: mammalian target of rapamycin; IGF: Insulin-like growth factor; CR: Complete response; PR: Partial response; RECIST: Response evaluation criteria in solid tumors; cRR: clinical response rate; PD: Progressive disease; SD: Stable disease; MRI: Magnetic resonance image; p-S6K1: phosphorylated S6 kinase 1; NGS: Next generation sequencing.</p></sec><sec><title>Competing interests</title><p>All authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>JK and WH drafted the manuscript and wrote the original protocol for the study. All authors participated in the design of the study. JK filed for ethical approvals from the KFDA and registered the trial on clinicaltrials.gov. WL performed the statistical analysis. EK designed the molecular study. MK was involved in the pharmaceutical process of SNUH and the process of patient enrollment. DN directed the entire process. All authors read and approved the final manuscript and are proceeding with the study in their respective centers.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/170/prepub">http://www.biomedcentral.com/1471-2407/14/170/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgments</title><p>This study is being supported by grant no 04-2012-0290 from the SNUH Research fund and by the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIP)(No. 2013005540).</p><p>Letrozole and metformin are being supplied by the pharmaceutical company, Shin Poong Pharm. Co., Ltd.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Lemieux</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>BE</given-names></name><name><surname>Parulekar</surname><given-names>WR</given-names></name><name><surname>Gelmon</surname><given-names>KA</given-names></name><name><surname>Hershman</surname><given-names>DL</given-names></name><name><surname>Hobday</surname><given-names>TJ</given-names></name><name><surname>Ligibel</surname><given-names>JA</given-names></name><name><surname>Mayer</surname><given-names>IA</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Whelan</surname><given-names>TJ</given-names></name><name><surname>Rastogi</surname><given-names>P</given-names></name><name><surname>Shepherd</surname><given-names>LE</given-names></name><article-title>Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>126</volume><issue>1</issue><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-1224-1</pub-id><pub-id pub-id-type="pmid">20976543</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Iliopoulos</surname><given-names>D</given-names></name><name><surname>Hirsch</surname><given-names>HA</given-names></name><name><surname>Struhl</surname><given-names>K</given-names></name><article-title>Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types</article-title><source>Can Res</source><year>2011</year><volume>71</volume><issue>9</issue><fpage>3196</fpage><lpage>3201</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3471</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Jiralerspong</surname><given-names>S</given-names></name><name><surname>Palla</surname><given-names>SL</given-names></name><name><surname>Giordano</surname><given-names>SH</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Liedtke</surname><given-names>C</given-names></name><name><surname>Barnett</surname><given-names>CM</given-names></name><name><surname>Hsu</surname><given-names>L</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><article-title>Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>20</issue><fpage>3297</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.19.6410</pub-id><pub-id pub-id-type="pmid">19487376</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Tisman</surname><given-names>G</given-names></name><article-title>Metformin, B(12), and enhanced breast cancer response to chemotherapy</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>2</issue><fpage>e19</fpage><comment>author reply e20</comment><pub-id pub-id-type="doi">10.1200/JCO.2009.25.7857</pub-id><pub-id pub-id-type="pmid">19949002</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Fenyk-Melody</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Ventre</surname><given-names>J</given-names></name><name><surname>Doebber</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Musi</surname><given-names>N</given-names></name><name><surname>Hirshman</surname><given-names>MF</given-names></name><name><surname>Goodyear</surname><given-names>LJ</given-names></name><name><surname>Moller</surname><given-names>DE</given-names></name><article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><issue>8</issue><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1172/JCI13505</pub-id><pub-id pub-id-type="pmid">11602624</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Hawley</surname><given-names>SA</given-names></name><name><surname>Gadalla</surname><given-names>AE</given-names></name><name><surname>Olsen</surname><given-names>GS</given-names></name><name><surname>Hardie</surname><given-names>DG</given-names></name><article-title>The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><issue>8</issue><fpage>2420</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.2337/diabetes.51.8.2420</pub-id><pub-id pub-id-type="pmid">12145153</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Zakikhani</surname><given-names>M</given-names></name><name><surname>Dowling</surname><given-names>R</given-names></name><name><surname>Fantus</surname><given-names>IG</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><article-title>Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>21</issue><fpage>10269</fpage><lpage>10273</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1500</pub-id><pub-id pub-id-type="pmid">17062558</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Pollak</surname><given-names>M</given-names></name><article-title>Insulin and insulin-like growth factor signalling in neoplasia</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><issue>12</issue><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1038/nrc2536</pub-id><pub-id pub-id-type="pmid">19029956</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Ligibel</surname><given-names>JA</given-names></name><name><surname>Stambolic</surname><given-names>V</given-names></name><article-title>Metformin in breast cancer: time for action</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>20</issue><fpage>3271</fpage><lpage>3273</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.1630</pub-id><pub-id pub-id-type="pmid">19487373</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Ennis</surname><given-names>M</given-names></name><name><surname>Clemons</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>M</given-names></name><name><surname>Fantus</surname><given-names>IG</given-names></name><article-title>Insulin-lowering effects of metformin in women with early breast cancer</article-title><source>Clin Breast Cancer</source><year>2008</year><volume>8</volume><issue>6</issue><fpage>501</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.3816/CBC.2008.n.060</pub-id><pub-id pub-id-type="pmid">19073504</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Bonanni</surname><given-names>B</given-names></name><name><surname>Puntoni</surname><given-names>M</given-names></name><name><surname>Cazzaniga</surname><given-names>M</given-names></name><name><surname>Pruneri</surname><given-names>G</given-names></name><name><surname>Serrano</surname><given-names>D</given-names></name><name><surname>Guerrieri-Gonzaga</surname><given-names>A</given-names></name><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Trabacca</surname><given-names>MS</given-names></name><name><surname>Galimberti</surname><given-names>V</given-names></name><name><surname>Veronesi</surname><given-names>P</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Aristarco</surname><given-names>V</given-names></name><name><surname>Bassi</surname><given-names>F</given-names></name><name><surname>Luini</surname><given-names>A</given-names></name><name><surname>Lazzeroni</surname><given-names>M</given-names></name><name><surname>Varricchio</surname><given-names>C</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Bruzzi</surname><given-names>P</given-names></name><name><surname>Decensi</surname><given-names>A</given-names></name><article-title>Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>21</issue><fpage>2593</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.3769</pub-id><pub-id pub-id-type="pmid">22564993</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><article-title>Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>21</issue><fpage>2698</fpage><lpage>2700</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.42.1677</pub-id><pub-id pub-id-type="pmid">22565000</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Semiglazov</surname><given-names>VF</given-names></name><name><surname>Semiglazov</surname><given-names>VV</given-names></name><name><surname>Dashyan</surname><given-names>GA</given-names></name><name><surname>Ziltsova</surname><given-names>EK</given-names></name><name><surname>Ivanov</surname><given-names>VG</given-names></name><name><surname>Bozhok</surname><given-names>AA</given-names></name><name><surname>Melnikova</surname><given-names>OA</given-names></name><name><surname>Paltuev</surname><given-names>RM</given-names></name><name><surname>Kletzel</surname><given-names>A</given-names></name><name><surname>Berstein</surname><given-names>LM</given-names></name><article-title>Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer</article-title><source>Cancer</source><year>2007</year><volume>110</volume><issue>2</issue><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1002/cncr.22789</pub-id><pub-id pub-id-type="pmid">17538978</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Mlineritsch</surname><given-names>B</given-names></name><name><surname>Tausch</surname><given-names>C</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Luschin-Ebengreuth</surname><given-names>G</given-names></name><name><surname>Jakesz</surname><given-names>R</given-names></name><name><surname>Ploner</surname><given-names>F</given-names></name><name><surname>Stierer</surname><given-names>M</given-names></name><name><surname>Melbinger</surname><given-names>E</given-names></name><name><surname>Menzel</surname><given-names>C</given-names></name><name><surname>Urbania</surname><given-names>A</given-names></name><name><surname>Fridrik</surname><given-names>M</given-names></name><name><surname>Steger</surname><given-names>G</given-names></name><name><surname>Wohlmuth</surname><given-names>P</given-names></name><name><surname>Gnant</surname><given-names>M</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><collab>Austrian Breast, Colorectal Cancer Study Group(ABCSG)</collab><article-title>Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)</article-title><source>Breast Cancer Res Treat</source><year>2008</year><volume>112</volume><issue>1</issue><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1007/s10549-007-9843-x</pub-id><pub-id pub-id-type="pmid">18158620</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Eiermann</surname><given-names>W</given-names></name><name><surname>Paepke</surname><given-names>S</given-names></name><name><surname>Appfelstaedt</surname><given-names>J</given-names></name><name><surname>Llombart-Cussac</surname><given-names>A</given-names></name><name><surname>Eremin</surname><given-names>J</given-names></name><name><surname>Vinholes</surname><given-names>J</given-names></name><name><surname>Mauriac</surname><given-names>L</given-names></name><name><surname>Ellis</surname><given-names>M</given-names></name><name><surname>Lassus</surname><given-names>M</given-names></name><name><surname>Chaudri-Ross</surname><given-names>HA</given-names></name><name><surname>Dugan</surname><given-names>M</given-names></name><name><surname>Borgs</surname><given-names>M</given-names></name><collab>Letrozole Neo-Adjuvant Breast Cancer Study Group</collab><article-title>Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><issue>11</issue><fpage>1527</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1023/A:1013128213451</pub-id><pub-id pub-id-type="pmid">11822750</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Semiglazov</surname><given-names>V</given-names></name><name><surname>van Dam</surname><given-names>P</given-names></name><name><surname>Manikhas</surname><given-names>A</given-names></name><name><surname>Bellet</surname><given-names>M</given-names></name><name><surname>Mayordomo</surname><given-names>J</given-names></name><name><surname>Campone</surname><given-names>M</given-names></name><name><surname>Kubista</surname><given-names>E</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Bianchi</surname><given-names>G</given-names></name><name><surname>Steinseifer</surname><given-names>J</given-names></name><name><surname>Mollow</surname><given-names>B</given-names></name><name><surname>Tokaji</surname><given-names>E</given-names></name><name><surname>Gardner</surname><given-names>H</given-names></name><name><surname>Phillips</surname><given-names>P</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>HA</given-names></name><name><surname>Dixon</surname><given-names>JM</given-names></name><name><surname>Jonat</surname><given-names>W</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><article-title>Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>16</issue><fpage>2630</fpage><lpage>2637</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.8391</pub-id><pub-id pub-id-type="pmid">19380449</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Goldenberg</surname><given-names>N</given-names></name><name><surname>Glueck</surname><given-names>CJ</given-names></name><name><surname>Loftspring</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><article-title>Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance</article-title><source>Metabolism</source><year>2005</year><volume>54</volume><issue>1</issue><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2004.08.007</pub-id><pub-id pub-id-type="pmid">15562389</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name><name><surname>Hoog</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Snider</surname><given-names>J</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>DeSchryver</surname><given-names>K</given-names></name><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Esserman</surname><given-names>LJ</given-names></name><name><surname>Unzeitig</surname><given-names>GW</given-names></name><name><surname>Margenthaler</surname><given-names>J</given-names></name><name><surname>Babiera</surname><given-names>GV</given-names></name><name><surname>Marcom</surname><given-names>PK</given-names></name><name><surname>Guenther</surname><given-names>JM</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Leitch</surname><given-names>M</given-names></name><name><surname>Hunt</surname><given-names>K</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name><article-title>Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z103</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>17</issue><fpage>2342</fpage><lpage>2349</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.31.6950</pub-id><pub-id pub-id-type="pmid">21555689</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Moon</surname><given-names>HG</given-names></name><name><surname>Ahn</surname><given-names>SK</given-names></name><name><surname>Shin</surname><given-names>HC</given-names></name><name><surname>You</surname><given-names>JM</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Kim</surname><given-names>TY</given-names></name><name><surname>Koo</surname><given-names>HR</given-names></name><name><surname>Chang</surname><given-names>JM</given-names></name><name><surname>Cho</surname><given-names>N</given-names></name><name><surname>Moon</surname><given-names>WK</given-names></name><name><surname>Noh</surname><given-names>DY</given-names></name><article-title>Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer</article-title><source>Breast Cancer Res</source><year>2012</year><volume>14</volume><issue>4</issue><fpage>R102</fpage><pub-id pub-id-type="doi">10.1186/bcr3221</pub-id><pub-id pub-id-type="pmid">22770227</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Nie</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Chau</surname><given-names>MK</given-names></name><name><surname>Yu</surname><given-names>HJ</given-names></name><name><surname>Bahri</surname><given-names>S</given-names></name><name><surname>Tseng</surname><given-names>T</given-names></name><name><surname>Nalcioglu</surname><given-names>O</given-names></name><name><surname>Su</surname><given-names>MY</given-names></name><article-title>Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI</article-title><source>Med Phys</source><year>2008</year><volume>35</volume><issue>12</issue><fpage>5253</fpage><lpage>5262</lpage><pub-id pub-id-type="doi">10.1118/1.3002306</pub-id><pub-id pub-id-type="pmid">19175084</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wullschleger</surname><given-names>S</given-names></name><name><surname>Shpiro</surname><given-names>N</given-names></name><name><surname>McGuire</surname><given-names>VA</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Woods</surname><given-names>YL</given-names></name><name><surname>McBurnie</surname><given-names>W</given-names></name><name><surname>Fleming</surname><given-names>S</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><article-title>Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice</article-title><source>Biochem J</source><year>2008</year><volume>412</volume><issue>2</issue><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1042/BJ20080557</pub-id><pub-id pub-id-type="pmid">18387000</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Anisimov</surname><given-names>VN</given-names></name><name><surname>Berstein</surname><given-names>LM</given-names></name><name><surname>Egormin</surname><given-names>PA</given-names></name><name><surname>Piskunova</surname><given-names>TS</given-names></name><name><surname>Popovich</surname><given-names>IG</given-names></name><name><surname>Zabezhinski</surname><given-names>MA</given-names></name><name><surname>Kovalenko</surname><given-names>IG</given-names></name><name><surname>Poroshina</surname><given-names>TE</given-names></name><name><surname>Semenchenko</surname><given-names>AV</given-names></name><name><surname>Provinciali</surname><given-names>M</given-names></name><name><surname>Re</surname><given-names>F</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><article-title>Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice</article-title><source>Exp Gerontol</source><year>2005</year><volume>40</volume><issue>8&#x02013;9</issue><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">16125352</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Anisimov</surname><given-names>VN</given-names></name><name><surname>Egormin</surname><given-names>PA</given-names></name><name><surname>Bershtein</surname><given-names>LM</given-names></name><name><surname>Zabezhinskii</surname><given-names>MA</given-names></name><name><surname>Piskunova</surname><given-names>TS</given-names></name><name><surname>Popovich</surname><given-names>IG</given-names></name><name><surname>Semenchenko</surname><given-names>AV</given-names></name><article-title>Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice</article-title><source>Bull Exp Biol Med</source><year>2005</year><volume>139</volume><issue>6</issue><fpage>721</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1007/s10517-005-0389-9</pub-id><pub-id pub-id-type="pmid">16224592</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Sherwin</surname><given-names>R</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><collab>American Diabetes A</collab><article-title>Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><issue>1</issue><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.2337/dc08-9025</pub-id><pub-id pub-id-type="pmid">18945920</pub-id></mixed-citation></ref></ref-list></back></article>